相关实验视频
Updated: Jul 8, 2025

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
用于糖尿病管理的多基诺林衍生物:合成,体外和体内方法
Faiz Talab1, Zainab2, Aftab Alam1
1Department of Chemistry, University of Malakand, PO Box 18800, Dir Lower, Khyber Pakhtunkhwa, Pakistan.
Future medicinal chemistry
|December 12, 2023
概括
新的多基诺林衍生物显示出作为α-葡萄糖酶抑制剂治疗2型糖尿病的前景. 这些化合物有效地降低了碳水化合物的吸收,提供了作为新型抗糖尿病药物候选者的潜力.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 2型糖尿病通常使用α-葡萄糖酶抑制剂来控制,这些抑制剂会降低肠道碳水化合物吸收.
- 聚氨衍生物因其作为有效抗糖尿病剂的潜力而得到认可.
研究的目的:
- 为了合成和评估新型的多基诺林衍生物,以检测它们在体外α-葡萄糖酶抑制活性.
- 确定潜在的化合物,用于开发新的2型糖尿病治疗方法.
主要方法:
- 合成十七种多基诺林衍生物 (化合物1-17).
- 在体外测试合成化合物的α-葡萄糖酶抑制活性.
- 分子对接研究以阐明与α-葡萄糖酶的结合机制.
主要成果:
- 所有合成的多基诺林衍生物都表现出显著的α-葡萄糖酶抑制活性.
- IC50值在1.23±0.03到73.85±0.61μM之间,与阿卡尔相比显示出强大的抑制作用.
- 接研究表明,轻微的结构变化影响了衍生品与酶的结合能力.
结论:
- 该研究确定了有前途的多基诺林衍生物作为新型抗糖尿病药物的潜在候选者.
- 这些发现支持继续研究用于2型糖尿病治疗的多基诺林支架.
相关概念视频
Oral Hypoglycemic Agents: Sulfonylureas
211
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
211
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Oral Hypoglycemic Agents: Biguanides and Glitazones
207
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
207
Glucagon-like Receptor Agonists
327
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
327
Insulin: Biosynthesis, Chemistry, and Preparation
387
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
387
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157

